Latest Idera Pharmaceuticals (IDRA) Headlines
Idera Pharmaceuticals Announces Appointment of Julian Baker and Dr. Kelvin Neu to its Board of Directors
Business Wire - Wed Mar 12, 7:30AM CDT
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Baker Brothers Investments' Julian C. Baker and Kelvin M. Neu, M.D., joined its Board of Directors, effective March 10, 2014. Founded in 2000, Baker Brothers Investments manages long-term investment funds focused on publicly traded life sciences companies, for major university endowments and foundations.
17.7% Return Seen to Date on SmarTrend Idera Pharmaceuticals Call (IDRA)
Comtex SmarTrend(R) - Mon Mar 10, 11:18AM CDT
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 1 month, Idera Pharmaceuticals has returned 17.65% as of today's recent price of $5.92.
Idera to Host Conference Call and Webcast to Report Fourth Quarter and Full Year 2013 Financial Results on Thursday, March 13, 2014
Business Wire - Thu Mar 06, 7:30AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that the Company will host a conference call and live audio webcast at 8:30 a.m. EDT on Thursday, March 13, 2014 to report its fourth quarter and full year 2013 financial results and provide a corporate update.
Uptrend Call Working As Idera Pharmaceuticals Stock Rises 14.1% (IDRA)
Comtex SmarTrend(R) - Mon Mar 03, 9:59AM CST
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 3 weeks, Idera Pharmaceuticals has returned 14.12% as of today's recent price of $5.74.
Idera to Present at the Cowen & Co. 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 7:30AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the Cowen & Co. 34th Annual Health Care Conference on Wednesday, March 5, 2014 at 10:00 a.m. EST at the Boston Marriott Copley Place in Boston, MA.
Idera Pharmaceuticals Up 16.0% Since SmarTrend Uptrend Call (IDRA)
Comtex SmarTrend(R) - Mon Feb 24, 9:26AM CST
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 2 weeks, Idera Pharmaceuticals has returned 15.98% as of today's recent price of $5.83.
Idera to Present at the 2014 RBC Capital Markets' Global Healthcare Conference
Business Wire - Tue Feb 18, 3:02PM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the 2014 RBC Capital Markets' Global Healthcare Conference on Tuesday, February 25, 2014 at 8:00 a.m. EST at the New York Palace Hotel in New York City.
Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants
Business Wire - Mon Feb 10, 3:15PM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) ("Idera" or the "Company") today announced the closing of its previously announced underwritten public offering of 7,867,438 shares of common stock at an offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at an offering price of $3.99 per pre-funded warrant, which is the per share public offering price for the common stock less the $0.01 per share exercise price. The shares of common stock in the offering include 1,026,188 shares issued upon the exercise in full by the underwriters of their over-allotment option at the offering price. The gross proceeds to Idera from this offering are expected to be approximately $40.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Idera and excluding the proceeds, if any, from the exercise of the pre-funded warrants.
2 Biotech Stocks Under $10 in Breakout Territory
at The Street - Fri Feb 07, 8:24AM CST
These under-$10 biotech stocks are within range of triggering breakout trades.
Idera to Present at 16th Annual BIO CEO & Investor Conference
Business Wire - Thu Feb 06, 7:30AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Sudhir Agrawal, D.Phil., Chief Executive Officer of Idera, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 2:30 p.m. EST at the Waldorf Astoria in New York City.
Idera Pharmaceuticals Inc prices public offering of common stock and pre-funded warrants at USD4.00 per share
M2 - Thu Feb 06, 5:26AM CST
Therapeutics company Idera Pharmaceuticals Inc (NasdaqCM:IDRA) said on Wednesday that it has priced its public offering of 6,841,250 shares of common stock at USD4.00 per share.
Stock to Watch: Idera Pharmaceuticals Down 8.6% (IDRA)
Comtex SmarTrend(R) - Wed Feb 05, 10:42AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 8.6% to $3.84 on 1.0x average daily volume. Thus far today, Idera Pharmaceuticals has traded 2.8 million shares, vs. average volume of 2.8 million shares per day. The stock has underperformed the Dow (-8.6% to the Dow's -0.1%) and underperformed the S&P 500 (-8.6% to the S&P's -0.4%) during today's trading.
Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Business Wire - Wed Feb 05, 8:09AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) ("Idera" or the "Company") today announced the pricing of an underwritten public offering of 6,841,250 shares of common stock for a public offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The gross proceeds to Idera from this offering are expected to be approximately $36 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Idera and excluding the proceeds, if any, from the exercise of the pre-funded warrants. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 1,026,188 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about February 10, 2014, subject to customary closing conditions.
Idera Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants
Business Wire - Tue Feb 04, 3:01PM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) ("Idera" or the "Company") today announced that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of its common stock in an underwritten public offering. Piper Jaffray & Co. and Cowen and Company, LLC are acting as joint bookrunning managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Innovative Food Holdings, Inc. Presents at MicroCapClub Invitational
Marketwire - Tue Feb 04, 7:45AM CST
Innovative Food Holdings, Inc. (OTCQB: IVFH) announced today it has been selected to present at the 2nd annual MicroCapClub Invitational.
Why Idera Pharmaceuticals, Inc. Shares Popped
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 22, 2:06PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Idera Pharmaceuticals , a clinical-stage...
Traders Get Bullish on Shares of Idera Pharmaceuticals, Shares Up 9.4% (IDRA)
Comtex SmarTrend(R) - Wed Jan 22, 10:42AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's best performing low-priced stocks, up 9.4% to $4.53 on 1.0x average daily volume. Thus far today, Idera Pharmaceuticals has traded 2.8 million shares, vs. average volume of 2.7 million shares per day. The stock has outperformed the Dow (9.4% to the Dow's -0.4%) and outperformed the S&P 500 (9.4% to the S&P's -0.1%) during today's trading.
Idera Announces Publication of New Data Demonstrating Impact of Inhibiting TLRs 7, 8, and 9 in a Preclinical Model of Autoimmune Disease
Business Wire - Wed Jan 22, 7:00AM CST
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced the publication of a study supporting the potential role of the suppression of Toll-like-receptors (TLRs) 7, 8, and 9 in the treatment of psoriasis. The data were published in the scientific journal PLOS ONE.
Idera Pharmaceuticals Has Returned 88.4% Since SmarTrend Recommendation (IDRA)
Comtex SmarTrend(R) - Tue Jan 14, 9:11AM CST
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on December 5th, 2013 at $2.68. In approximately 1 month, Idera Pharmaceuticals has returned 88.41% as of today's recent price of $5.04.
Today's Dead Cat Bounce Stock Is Idera Pharmaceuticals (IDRA)
at The Street - Thu Jan 09, 8:48AM CST
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate
Idera Pharmaceuticals Announces Appointment of Julian Baker and Dr. Kelvin Neu to its Board of Directors
Business Wire - Wed Mar 12, 7:30AM CDT
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Baker Brothers Investments' Julian C. Baker and Kelvin M. Neu, M.D., joined its Board of Directors, effective March 10, 2014. Founded in 2000, Baker Brothers Investments manages long-term investment funds focused on publicly traded life sciences companies, for major university endowments and foundations.
17.7% Return Seen to Date on SmarTrend Idera Pharmaceuticals Call (IDRA)
Comtex SmarTrend(R) - Mon Mar 10, 11:18AM CDT
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 1 month, Idera Pharmaceuticals has returned 17.65% as of today's recent price of $5.92.
Idera to Host Conference Call and Webcast to Report Fourth Quarter and Full Year 2013 Financial Results on Thursday, March 13, 2014
Business Wire - Thu Mar 06, 7:30AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that the Company will host a conference call and live audio webcast at 8:30 a.m. EDT on Thursday, March 13, 2014 to report its fourth quarter and full year 2013 financial results and provide a corporate update.
Uptrend Call Working As Idera Pharmaceuticals Stock Rises 14.1% (IDRA)
Comtex SmarTrend(R) - Mon Mar 03, 9:59AM CST
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 3 weeks, Idera Pharmaceuticals has returned 14.12% as of today's recent price of $5.74.
Idera to Present at the Cowen & Co. 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 7:30AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the Cowen & Co. 34th Annual Health Care Conference on Wednesday, March 5, 2014 at 10:00 a.m. EST at the Boston Marriott Copley Place in Boston, MA.
Idera Pharmaceuticals Up 16.0% Since SmarTrend Uptrend Call (IDRA)
Comtex SmarTrend(R) - Mon Feb 24, 9:26AM CST
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 2 weeks, Idera Pharmaceuticals has returned 15.98% as of today's recent price of $5.83.
Idera to Present at the 2014 RBC Capital Markets' Global Healthcare Conference
Business Wire - Tue Feb 18, 3:02PM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the 2014 RBC Capital Markets' Global Healthcare Conference on Tuesday, February 25, 2014 at 8:00 a.m. EST at the New York Palace Hotel in New York City.
Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants
Business Wire - Mon Feb 10, 3:15PM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) ("Idera" or the "Company") today announced the closing of its previously announced underwritten public offering of 7,867,438 shares of common stock at an offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at an offering price of $3.99 per pre-funded warrant, which is the per share public offering price for the common stock less the $0.01 per share exercise price. The shares of common stock in the offering include 1,026,188 shares issued upon the exercise in full by the underwriters of their over-allotment option at the offering price. The gross proceeds to Idera from this offering are expected to be approximately $40.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Idera and excluding the proceeds, if any, from the exercise of the pre-funded warrants.
2 Biotech Stocks Under $10 in Breakout Territory
at The Street - Fri Feb 07, 8:24AM CST
These under-$10 biotech stocks are within range of triggering breakout trades.
Idera to Present at 16th Annual BIO CEO & Investor Conference
Business Wire - Thu Feb 06, 7:30AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Sudhir Agrawal, D.Phil., Chief Executive Officer of Idera, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 2:30 p.m. EST at the Waldorf Astoria in New York City.
Idera Pharmaceuticals Inc prices public offering of common stock and pre-funded warrants at USD4.00 per share
M2 - Thu Feb 06, 5:26AM CST
Therapeutics company Idera Pharmaceuticals Inc (NasdaqCM:IDRA) said on Wednesday that it has priced its public offering of 6,841,250 shares of common stock at USD4.00 per share.
Stock to Watch: Idera Pharmaceuticals Down 8.6% (IDRA)
Comtex SmarTrend(R) - Wed Feb 05, 10:42AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 8.6% to $3.84 on 1.0x average daily volume. Thus far today, Idera Pharmaceuticals has traded 2.8 million shares, vs. average volume of 2.8 million shares per day. The stock has underperformed the Dow (-8.6% to the Dow's -0.1%) and underperformed the S&P 500 (-8.6% to the S&P's -0.4%) during today's trading.
Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Business Wire - Wed Feb 05, 8:09AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) ("Idera" or the "Company") today announced the pricing of an underwritten public offering of 6,841,250 shares of common stock for a public offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The gross proceeds to Idera from this offering are expected to be approximately $36 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Idera and excluding the proceeds, if any, from the exercise of the pre-funded warrants. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 1,026,188 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about February 10, 2014, subject to customary closing conditions.
Idera Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants
Business Wire - Tue Feb 04, 3:01PM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) ("Idera" or the "Company") today announced that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of its common stock in an underwritten public offering. Piper Jaffray & Co. and Cowen and Company, LLC are acting as joint bookrunning managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Innovative Food Holdings, Inc. Presents at MicroCapClub Invitational
Marketwire - Tue Feb 04, 7:45AM CST
Innovative Food Holdings, Inc. (OTCQB: IVFH) announced today it has been selected to present at the 2nd annual MicroCapClub Invitational.
Why Idera Pharmaceuticals, Inc. Shares Popped
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 22, 2:06PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Idera Pharmaceuticals , a clinical-stage...
Traders Get Bullish on Shares of Idera Pharmaceuticals, Shares Up 9.4% (IDRA)
Comtex SmarTrend(R) - Wed Jan 22, 10:42AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's best performing low-priced stocks, up 9.4% to $4.53 on 1.0x average daily volume. Thus far today, Idera Pharmaceuticals has traded 2.8 million shares, vs. average volume of 2.7 million shares per day. The stock has outperformed the Dow (9.4% to the Dow's -0.4%) and outperformed the S&P 500 (9.4% to the S&P's -0.1%) during today's trading.
Idera Announces Publication of New Data Demonstrating Impact of Inhibiting TLRs 7, 8, and 9 in a Preclinical Model of Autoimmune Disease
Business Wire - Wed Jan 22, 7:00AM CST
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced the publication of a study supporting the potential role of the suppression of Toll-like-receptors (TLRs) 7, 8, and 9 in the treatment of psoriasis. The data were published in the scientific journal PLOS ONE.
Idera Pharmaceuticals Has Returned 88.4% Since SmarTrend Recommendation (IDRA)
Comtex SmarTrend(R) - Tue Jan 14, 9:11AM CST
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on December 5th, 2013 at $2.68. In approximately 1 month, Idera Pharmaceuticals has returned 88.41% as of today's recent price of $5.04.
Today's Dead Cat Bounce Stock Is Idera Pharmaceuticals (IDRA)
at The Street - Thu Jan 09, 8:48AM CST
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate
